Peter Burke, DO
Nephrology · Newark, DENPI 1902126493
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $620, 6.3 times the $99 reported in 2019. That places this record below the midpoint for nephrology clinicians in DE, where the typical reported total is $2,465.
Across 105 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$277
- AstraZeneca$253
- Vifor Pharma, Inc.$209
- Fresenius USA Marketing, Inc.$187
- Veloxis Pharmaceuticals, Inc.$176
- Amgen$175
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,31999%
- Education$331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 10 | $277 |
| AstraZeneca(2 entities) | 9 | $253 |
| Vifor Pharma, Inc. | 7 | $209 |
| Fresenius USA Marketing, Inc. | 11 | $187 |
| Veloxis Pharmaceuticals, Inc. | 6 | $176 |
| Amgen | 9 | $175 |
| Otsuka America Pharmaceutical, Inc. | 7 | $139 |
| Calliditas Therapeutics US Inc. | 7 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $116 |
| Merck | 6 | $114 |
| Bayer | 4 | $76 |
| Daiichi Sankyo Inc. | 4 | $68 |
| Invivyd Inc | 2 | $56 |
| Sanofi | 2 | $43 |
| Boehringer Ingelheim | 2 | $39 |
| Kyowa Kirin, Inc. | 2 | $38 |
| Travere Therapeutics, Inc. | 2 | $35 |
| Gilead | 1 | $27 |
| Aurinia Pharma U.S., Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $25 |
| Angiodynamics, Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
| Novartis | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Akebia Therapeutics Inc | 1 | $16 |
| OPKO Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$125
How this compares
$2,352 in reported general payments places this provider in the 45th percentile of 49 nephrology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LivtencityMaribavir | 11 | $278,629 |
| PrevymisLetermovir | 12 | $120,446 |
| Cinacalcet Hcl | 102 | $66,489 |
| Valganciclovir Hcl | 67 | $23,562 |
| Entecavir | 45 | $11,352 |
| Leflunomide | 100 | $7,252 |
| Methenamine Hippurate | 85 | $6,011 |
| Cefpodoxime Proxetil | 27 | $2,384 |
| Nifedipine ErNifedipine | 50 | $1,680 |
| Calcitriol | 41 | $1,186 |
| Losartan Potassium | 66 | $1,081 |
| Potassium Chloride | 40 | $995 |
| Tamsulosin Hcl | 65 | $853 |
| Amlodipine Besylate | 99 | $785 |
| Hydralazine Hcl | 64 | $751 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Livtencity | $116 | $278,62911 claims |
| MerckPrevymis | $114 | $120,44612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 49 nephrology providers in Delaware.
Other nephrology in Newark
- Prayus TailorNewark$127K
- William DahmsNewark$94K
- Theodore SaadNewark$26K
- Nealanjon DasNewark$6K
- Manthodi FaisalNewark$6K
- Piyaporn ApivatanagulNewark$5K
- Lindsey SlaterNewark$4K
- Christopher CanfieldNewark$3K
- Farhana ChowdhuryNewark$3K
- Feroz Abubacker KaniyamparambilNewark$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.